News
Click here for news in Danish.
December 10, 2014 | Company Announcements
Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate CancerDecember 04, 2014 | Company Announcements
Bavarian Nordic Announces First Subject Dosed with MVA-BN® Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines November 30, 2014 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/SNovember 26, 2014 | Company Announcements
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants November 18, 2014 | Company Announcements
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants November 17, 2014 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchNovember 13, 2014 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2014 October 31, 2014 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/SOctober 29, 2014 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Completion of a Direct Placement to Johnson & Johnson Development CorporationOctober 22, 2014 | Company Announcements
Bavarian Nordic Announces Expanded Collaboration with Janssen on MVA-BN® for Additional Infectious Disease TargetsOctober 22, 2014 | Company Announcements
Bavarian Nordic Announces Additional Details Concerning the Issue of Shares to Johnson & Johnson Development CorporationOctober 22, 2014 | Company Announcements
Bavarian Nordic Enters Licensing and Supply Agreement with Janssen on MVA-BN® Ebola VaccineOctober 22, 2014 | Company Announcements
Bavarian Nordic Provides Update on Business Activities and Reports Preliminary Interim Financial Results for the First Nine Months of 2014September 23, 2014 | Company Announcements
Bavarian Nordic issues Financial Calendar for 2015September 04, 2014 | Company Announcements
Bavarian Nordic Announces Exercise of Contract Option by the U.S. Government for Continued Supply of IMVAMUNE® Smallpox VaccineAugust 28, 2014 | Company Announcements
Bavarian Nordic Announces First Half 2014 ResultsAugust 26, 2014 | Company Announcements
Bavarian Nordic Receives Order from the Canadian Government to Supply IMVAMUNE® Smallpox VaccineJuly 24, 2014 | Company Announcements
Bavarian Nordic Announces First Patient Treated in a Phase 1 Study of MVA-BN® Brachyury in Advanced CancerMay 31, 2014 | Company Announcements
Total number of voting rights and share capital in Bavarian Nordic A/SMay 28, 2014 | Company Announcements
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with suchMay 28, 2014 | Company Announcements
Bavarian Nordic Announces Appointment of Paul Chaplin, Ph.D. as President & CEO May 27, 2014 | Company Announcements
Bavarian Nordic A/S Issues New Shares in Connection with Exercise of Warrants May 15, 2014 | Company Announcements
Bavarian Nordic to Present New Evidence for Mechanism of Action for PROSTVAC Immunotherapy at the 2014 ASCO Annual MeetingMay 15, 2014 | Company Announcements
Bavarian Nordic to Present Data Combining its Cancer Immunotherapies with Immune Checkpoint Inhibitors at the 2014 ASCO Annual MeetingMay 14, 2014 | Company Announcements
Bavarian Nordic Announces First Quarter 2014 Results